STI-9199 neutralizing antibody (nAb) nasal drops prevent productive infections when given to animals 24 hours before they are exposed to COVID. This intranasal STI-9199 may potentially give the option ...

STI-9167 neutralizing antibody (nAb) maintains high neutralization potency against the recently emerging Omicron sublineage BA.2 as was previously demonstrated for the Omicron sublineage BA.1 viruses, ...

The Indian drug regulator's subject expert committee on Wednesday recommended full approval for Covishield and Covaxin, the two COVID-19 vaccines that have dominated the country's inoculation drive.

Covishield and Covaxin are the two vaccines used in the majority of the Indian population. The four permutations for a booster dose evaluated in this study are primary immunization with Covishield ...

A first ever comparative study has revealed that Covishield outperformed Covaxin as vaccine during the Covid-19 pandemic. The study not only provides comparison data of both vaccines but also paves ...

Researchers from the National Centre for Biological Sciences (NCBS) have recently published a new study in The Lancet Regional Health Southeast Asia on March 6. The study provided significant insights ...

Recent revelations regarding a potential rare side effect of AstraZeneca's COVID-19 vaccine, Covishield, have sparked concerns among the public. A legal submission by AstraZeneca admitted that their ...

The two vaccinations against Covid-19 Covaxin and Covishield were highly effective against severe Covid-19 among Indians during the highly transmissible Delta variant in the second wave of the ...

Neutralising antibody responses against the SARS-COV-2 virus and its variants of concern (VoC) are higher among Covishield recipients than those who took the indigenously made Covaxin, according to a ...

A booster dose of Covishield offers the best immune response, irrespective of whether the primary doses were of Covishield or Covaxin, according to a new study conducted in India and published in The ...

AstraZeneca has admitted for the first time in court documents that its Covid-19 vaccine, sold globally under the brand names Covishield and Vaxzevria among others, may lead to a rare side-effect.

The World Health Organization had greenlit the use of Covishield two years ago for individuals aged 18 and older. (HT_PRINT) A well known British-Indian cardiologist has flagged the cardiovascular ...